Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/25789
Başlık: Orta-şiddetli psoriazisli olgularda infliksimab ile klinik deneyimimiz: Retrospektif çalışma
Diğer Başlıklar: Our clinic experience with infliximab in cases with moderate-severe psoriasis: A retrospective study
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.
0000-0002-0144-3263
Başkan, Emel Bülbül
Öztürk, Zerrin Yazıcı
Erdem, Hatice
Sarıcaoğlu, Hayriye
AAH-1388-2021
6602518817
36137752900
57197698218
6603722836
Anahtar kelimeler: Infliximab
Psoriasis
TNF-alpha
Necrosis-factor-alpha
Tnf-alpha
Pustular psoriasis
Arthritis
Etanercept
Efficacy
Therapy
Dermatology
Yayın Tarihi: Eyl-2009
Yayıncı: Deri ve Zührevi Hastalıklar Derneği
Atıf: Başkan, E. B. vd. (2009). "Orta-şiddetli psoriazisli olgularda infliksimab ile klinik deneyimimiz: Retrospektif çalışma". Türkderm Deri Hastalıkları ve Frengi Arşivi, 43(3), 95-99.
Özet: Background and Design: In this study, we aimed to evaluate the efficacy, safety and side effects of infliximab therapy in patients followed up in our clinic with moderate-severe psoriatic patients unresponsive to conventional therapies. Material and Method: Twenty-six psoriasis patients who were given infliximab therapy in our clinic between years 20062008, were retrospectively analyzed for their demographical clinical features, changes in PASI score, duration, efficacy and adverse effects of the therapy. Results: There were 15 female and 11 male psoriasis patients; ages ranging from 18 to 70 years (45.2 +/- 12.9). 17 of them were diagnosed as generalize plaque type psoriasis, 2 as eritrodermic psoriasis, 5 as generalize pustular, two of them as palmoplantar pustular psoriasis. Thirteen have associated psoriatic arthritis. All patients received 5 mg/kg intravenous infliximab infusion at weeks 0, 2, and 6, followed by every 8 weeks. Number of infliximab therapy sections was ranging from 2 to 16 and duration of treatment from 1 month to 28 months. Improvement in PASI between pretreatment and after induction therapy was statistically significant (p<0.05). Additional systemic treatment for disease activation was applied to patients receiving infliximab monotherapy at 14.-38. weeks. We observed allergic infusion reactions in 15.4% of the patients. Conclusion: In compatible with data in literature, we found that infliximab therapy provides a rapid clinical response in patients (generalized, eritrodermic and/or pustular psoriasis) who are unresponsive to immunosupressive agents or in cases which these treatment modalities cannot be used because of side effects.
URI: https://jag.journalagent.com/turkderm/pdfs/TURKDERM_43_3_95_99.pdf
http://hdl.handle.net/11452/25789
ISSN: 1019-214X
1308-6294
Koleksiyonlarda Görünür:Scopus
TrDizin
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Başkan_vd_2009.pdf221.47 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons